FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.289,13 -343,56 (-0,58%)
Trevena, Inc. (TRVN)
Dopo ore:
| Chiusura precedente | 0,4090 |
| Aperto | 0,3978 |
| Denaro | 0,2800 x 200 |
| Lettera | 0,5070 x 200 |
| Min-Max giorno | 0,3835 - 0,4089 |
| Intervallo di 52 settimane | 0,3000 - 3,2800 |
| Volume | |
| Media Volume | 208.769 |
| Capitalizzazione | 7,164M |
| Beta (5 anni mensile) | 1,10 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,1600 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 6,00 |
GlobeNewswireTrevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies
TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia, bradycardia, or change in blood pressure reported CHESTERBROOK, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported topline
- GlobeNewswire
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into respiratory compromise rates VOLITION data to be presented at the American Society of Anesthesiologists Meeting October 13-17, 2023 Company will also participate in the BIO Investor Forum October 17-18, 2023 CHESTERBROOK, Pa., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceut
- GlobeNewswire
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena’s partner in China New OLINVYK respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023 Three OLINVYK abstracts accepted for presentation at upcoming American Society of Anesthesiologists Meeting in 4Q 2023 Company to participate in upcoming HC Wainwright conference (September 11-13) Company to Hold
